Press releases

17 September, 2021

Abliva to participate in World Mitochondrial Disease Week 2021

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces that the compan ...

17 September, 2021

Abliva drug candidate NV354 to progress to clinical development following positive regulatory review

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), today announced that a se ...

16 September, 2021

Meet Abliva’s CEO live: Fireside Chat in Stockholm and Lund

19 August, 2021

Regulatory

Abliva AB Interim Report January – June 2021

Second quarter summary

31 May, 2021

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announce that the number of shares and votes in the Company has increased by 74,065,306, as a result of a directed new issue of shares resolved by the Board of ...

20 May, 2021

Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2021 held its Annual General Meeting (“AGM”). Due to the continued spread of the coronavirus and the authorities’ regula ...

20 May, 2021

Regulatory

Abliva AB Interim Report January – March 2021

First quarter summary

19 May, 2021

Regulatory

Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients

30 April, 2021

Regulatory

Abliva publishes prospectus and new information contained in the prospectus

Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, tod ...

30 April, 2021

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announce that the number of shares and votes in the Company has increased by 32,601,360 as a result of a directed new issue of shares resolved by the Board of ...

29 April, 2021

Regulatory

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. Due to the continued spread of the coronavirus and the authorities’ regulations/advice o ...

27 April, 2021

Regulatory

Abliva AB publishes 2020 Annual report

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the English version of the Annual report for 2020 is now available on the company’s website, www.abliva.com.